Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234195 · ClinicalTrials.gov registry record · Phase 4
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
A Phase 4 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00234195 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 25 participants.
The verdict
NCT00234195, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
* To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. * To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients
Interventions
- DRUG bupropion extended release (Wellbutrin XL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234195
The ClinicalTrials.gov registry entry for NCT00234195 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bupropion extended release (Wellbutrin XL) is the first listed.
NCT00234195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234195 about?
NCT00234195 is a clinical study titled "Wellbutrin XL, Major Depressive Disorder and Breast Cancer". * To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer. * To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these patients
What is the current status of trial NCT00234195?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2005-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00234195?
The interventions under investigation include: bupropion extended release (Wellbutrin XL) (DRUG).
Who is sponsoring clinical trial NCT00234195?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.